Literature DB >> 12202532

Widespread expression of an exogenous gene in the eye after intravenous administration.

Chunni Zhu1, Yun Zhang, William M Pardridge.   

Abstract

PURPOSE: Gene-targeting technology and tissue-specific gene promoters were used to produce widespread expression of an exogenous gene throughout the eye, including the retinal pigmented epithelium, after noninvasive intravenous administration of a nonviral plasmid formulation.
METHODS: An expression plasmid encoding bacterial beta-galactosidase, under the influence of either the simian virus (SV)40 promoter or the glial fibrillary acidic protein (GFAP) gene promoter, was packaged in the interior of 85-nm pegylated immunoliposomes (PIL) targeted to transferrin receptor (TfR)-rich structures with the rat 8D3 monoclonal antibody (mAb) to the mouse TfR. Plasmid DNA was packaged in the 8D3-PIL and injected intravenously into adult female BALB/c mice at a dose of 5 micro g DNA per mouse. The eyes were removed 48 hours later, and frozen sections were prepared for beta-galactosidase histochemistry and rhodopsin, TfR, or GFAP immunocytochemistry.
RESULTS: There was diffuse expression of the SV40/beta-galactosidase gene in the retinal pigmented epithelium. The cellular specificity of gene expression was influenced by the promoter used in the gene construct, evidenced by the fact that gene expression in the inner retina was induced with the GFAP promoter. The beta-galactosidase gene was also widely expressed in the TfR-rich epithelial structures of the eye, including the ciliary body, the iris, the sebaceous glands of the tarsal plate, and the epithelium of the cornea. When the anti-TfR mAb on the PIL was replaced with the rat IgG isotype control, there was no gene expression in the eye.
CONCLUSIONS: Widespread expression of an exogenous gene throughout the retina pigmented epithelium or other structures of the eye is possible with a noninvasive intravenous administration of a nonviral plasmid that is reformulated with gene-targeting technology. The cellular specificity of gene expression in the eye can be regulated with the use of cell-specific gene promoters.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202532

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

Review 1.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

Review 2.  shRNA and siRNA delivery to the brain.

Authors:  William M Pardridge
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

Review 3.  Inner blood-retinal barrier transporters: role of retinal drug delivery.

Authors:  Ken-ichi Hosoya; Masanori Tachikawa
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

4.  A high-throughput biophotonics instrument to screen for novel ocular photosensitizing therapeutic agents.

Authors:  Mark C Butler; Patrick N Itotia; Jack M Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

Review 5.  Non-viral therapeutic approaches to ocular diseases: An overview and future directions.

Authors:  Rahel Zulliger; Shannon M Conley; Muna I Naash
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

Review 6.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

7.  A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo.

Authors:  Sarah Parker Read; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  J Gene Med       Date:  2010-01       Impact factor: 4.565

8.  Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV.

Authors:  S R Singh; H E Grossniklaus; S J Kang; H F Edelhauser; B K Ambati; U B Kompella
Journal:  Gene Ther       Date:  2009-02-05       Impact factor: 5.250

Review 9.  Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain.

Authors:  William M Pardridge
Journal:  Front Med Technol       Date:  2020-11-16

Review 10.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.